Kava hepatotoxicity: A European view

New Zealand Medical Journal

Volumn 121, Issue 1283, 2008, Pages 90-98

  Teschke, Rolf ^a   Schwarzenboeck, Alexander ^a   Akinci, Ahmet ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETONE; ALCOHOL; FENOFIBRATE; HYPERICUM PERFORATUM EXTRACT; IBUPROFEN; KAVA; LISINOPRIL; PHENOBARBITAL; PLANT EXTRACT;

ANXIETY DISORDER; AQUEOUS SOLUTION; ARTICLE; AUSTRALIA; CULTIVAR; DIET SUPPLEMENTATION; DRUG LABELING; DRUG MANUFACTURE; DRUG OVERDOSE; DRUG QUALITY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; GERMANY; HERBAL MEDICINE; HUMAN; LIVER TOXICITY; NEW CALEDONIA; PATIENT COMPLIANCE; PIPER METHYSTICUM; PRACTICE GUIDELINE; RECOMMENDED DRUG DOSE; RELIABILITY; RISK FACTOR; SWITZERLAND; TREATMENT DURATION; UNITED STATES; CHEMICALLY INDUCED DISORDER; EUROPE; LIVER DISEASE; PHYTOTHERAPY; REVIEW;

AUSTRALIA; EUROPE; HUMANS; KAVA; LIVER DISEASES; PHYTOTHERAPY; PLANT EXTRACTS;

EID: 55249125241     PISSN: None     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Moulds RFW, Malani J. Kava: Herbal panacea or liver poison? Med J Aust. 2003;178:451-3. http://www.mja.com.au/public/issues/178_09_050503/ mou10043_fm.html
2. Pittler M H, Ernst E. Kava extract for treating anxiety (Cochrane Review). In: CochSane Library. Oxford: Update Software; 2003:Issue I.
3. Teschke R, Gaus W, Loew D. Kava extracts: Safety and risks including rare hepatotoxicity. Phytomedicine. 2003;10:440-6.
4. Schmidt M, Morgan M, Bone K, McMillan J. Kava: A risk-benefit assessment. In: Mills M, Bone K (Eds). The essential guide to herbal safety. St Louis (Missouri): Elsevier Churchill Livingstone; 2005:155-221.
5. BfArM Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn. Federal Institute for Drugs and Medicinal Products in Germany), 2002. http://www.bfarm.de/de/arzneimittel/am_sicher/stufenpl/ Besch-kava-Final.pdf
6. Russmann S, Barguil Y, Cabalion P, et al. Hepatic injury due to traditional aqueous extracts of kava root in New Caledonia. Eur J Gastroenterol Hepatol. 2003;15:1033-6.
7. Denham A, McIntyre M, Whitehouse J. Kava - the unfolding story: Report on a work-in-progress. J Altern Complement Med. 2002;8:237-63.
8. Stevenson C, Huntly A, Ernst E: A systematic review of the safety of kava extract in the treatment of anxiety. Drug Safety. 2002;25:251-61.
9. Schulze J, Raasch W, Siegers CP. Toxicity of kava pyrones, drug safety and precautions - a case study. Phytomedicine. 2003;10, Suppl IV:68-73.
10. Loew D, Franz G. Quality aspects of traditional and industrial kava-extracts. Phytomedicine. 2003;10:610-612.
11. Stickel F, Baumüller HM, Seitz K, Vasilakis D, Seitz G, Seitz HK et al. Hepatitis induced by kava (piper methysticum rhizoma). J Hepatol. 2003;39:62-7.
12. Ernst E. Kava update: A European perspective. N Z Med J. 2004;117 (1205). http://www.nzmj.com/journal/117-1205/1143
13. Clouatre DL. Kava kava: Examining new reports of toxicity. Toxicol Lett. 2004;150:85-96.
14. Block KI, Gyllenhaal C, Mead MN. Safety and efficacy of herbal sedatives in cancer care. Integr Cancer Ther. 2004;3:128-48.
15. Schmidt M. Quality criteria for kava. Herbal Gram. 2007;73:45-9.
16. Teschke R, Schwarzenboeck A, Hennermann KH. Kava hepatotoxicity: A clinical survey and critical analysis of suspected 26 cases. Eur J Gastroenterol Hepatol. 2008 (in press).
17. Danan G, Bénichou C. Causality assessment of adverse reactions to drugs - I. A novel method based on the conclusions of international consensus meetings: Application to drug-induced liver injuries. J Clin Epidemiol. 1993;46:1323-30.
18. Gow PJ, Connelly NJ, Hill RL, et al. Fatal fulminant hepatic failure induced by a natural therapy containing kava. Med J Aust. 2003;178:442-3.
19. Mathews JD., Riley MD, Fejo L, et al. Effects of the heavy usage of kava on physical health: Summary of a pilot survey in an aboriginal community. Med J Aust. 1988;148:548-55.
20. Clough AR, Bailie RS, Currie B. Liver function test abnormalities in users of aqueous kava extracts. J Toxicol/Clin Toxicol. 2003;41:821-9.
21. Humberston CL, Akhtar J, Krenzelok EP. Acute hepatitis induced by kava kava. J Toxicol/Clin Toxicol. 2003;41:109-13.
22. Currie BJ, Clough AR. Kava hepatotoxicity with Western herbal products: does it occur with traditional kava use? Med J Aust. 2003;178:421-2.
23. Lebot V, Merlin M, Lindstrom L. Kava, the Pacific elixir. New Haven: Yale University Press; 1992.
24. Lechtenberg M, Quandt B, Schmidt M, Nahrstedt A. Is the alkaloid pipermethystine connected with the claimed liver toxicity of kava products? Pharmazie. 2008;63;71-4.
25. Anke J, Ramzan I. Pharmacokinetic and pharmacodynamic drug interactions with kava (Piper methysticum Forst. f.). J Ethnopharmacol. 2004;93:153-60.